Did you have any side effects with this medicine?
What is Roxithromycin-RL?
Erythromycin belongs to the family of medicines called antibiotics. Erythromycin ophthalmic preparations are used to treat infections of the eye. They also may be used to prevent certain eye infections of newborn babies, such as neonatal conjunctivitis and ophthalmia neonatorum. They may be used with other medicines for some eye infections.
Erythromycin is available only with your doctor's prescription.
Roxithromycin-RL is indicated for the treatment of the following types of mild to
moderately severe infections caused by or likely to be caused by susceptible
micro-organisms: • upper respiratory tract infection - acute pharyngitis, tonsillitis and
• dental infections
• lower respiratory tract infection - acute bronchitis; acute exacerbations
of chronic bronchitis and community acquired pneumonia
• skin and skin structure infections
• non-gonococcal urethritis.
How should I use Roxithromycin-RL?
Use exactly as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
Do not use erythromycin topical to treat any skin condition that has not been checked by your doctor.
Wash your hands before and after using this medicine.
Clean and dry the skin area before you apply erythromycin topical. Spread the medicine on lightly, without rubbing it in.
Erythromycin topical is usually applied once or twice daily. Follow your doctor's instructions.
It may take up to 12 weeks before your symptoms improve. Keep using the medication as directed and tell your doctor if your symptoms do not improve after 6 weeks of treatment.
Store at room temperature away from moisture and heat. Keep the tube or bottle tightly closed when not in use.
The gel form of this medicine is flammable. Do not use near high heat or open flame.
Uses of Roxithromycin-RL in details
Roxithromycin-RL is used to treat ear, nose and throat infections, pneumonia (lung infection), skin infections and infections of the genitalia.
Roxithromycin-RL is a semi-synthetic macrolide antibiotic. It is very similar in composition, chemical structure and mechanism of action to erythromycin, azithromycin, or clarithromycin. Roxithromycin-RL prevents bacteria from growing, by interfering with their protein synthesis. Roxithromycin-RL binds to the subunit 50S of the bacterial ribosome, and thus inhibits the translocation of peptides. Roxithromycin-RL has similar antimicrobial spectrum as erythromycin, but is more effective against certain gram-negative bacteria, particularly Legionella pneumophila. It can treat respiratory tract, urinary and soft tissue infections. It is in the United States, but is available in Australia.
Adults: Recommended Dose: Mild to Moderate Acute Bacterial Exacerbations of COPD, Pneumonia of Mild Severity, Pharyngitis, Tonsillitis and Uncomplicated Skin and Skin Structure Infections: 500 mg as a single dose on the 1st day followed by 250 mg once daily on days 2 through 5.
Genital Ulcer Disease: 1000 mg as single dose.
Urethritis and Cervicitis: 2000 mg as single dose. Capsule should be given at least 1 hr before or 2 hrs after a meal. Azithromycin tablets can be taken with or without food.
Children: Use of azithromycin in children <6 months is not recommended.
Roxithromycin-RL has a much lower affinity for cytochrome P450 than erythromycin, and consequently has fewer interactions. Interactions may be observed, however, with drugs that bind to alpha-1-acid glycoprotein, e.g. disopyramide. Roxithromycin-RL does not appear to interact with oral contraceptives, prednisolone, carbamazepine, ranitidine or antacids. Theophylline. A study in normal subjects concurrently administered Roxithromycin-RL and theophylline has shown some increase in the plasma concentration of the latter. While a change in dosage is usually not required, patients with high levels of theophylline at commencement of treatment should have levels monitored. Ergot alkaloids. Reactions of ergotism with possible peripheral necrosis have been reported after concomitant therapy of macrolides with vasoconstrictive ergot alkaloids, particularly ergotamine and dihydroergotamine. Because a clinical interaction with Roxithromycin-RL cannot be excluded, administration of Roxithromycin-RL to patients taking ergot alkaloids is contraindicated. Disopyramide. An in vitro study has shown that Roxithromycin-RL can displace protein bound disopyramide; such an effect in vivo could result in increased serum levels of disopyramide. Consequently, ECG and, if possible, disopyramide serum levels should be monitored. Terfenadine. Some macrolide antibiotics (e.g. erythromycin) may increase serum levels of terfenadine. This can result in severe cardiovascular adverse events, including QT prolongation, torsades de pointes and other ventricular arrhythmias. Such a reaction has not been documented with Roxithromycin-RL, which has a much lower affinity for cytochrome P450 than erythromycin. However, in the absence of a systematic interaction study, concomitant administration of Roxithromycin-RL and terfenadine is not recommended. Astemizole, cisapride, pimozide. Other drugs, such as astemizole, cisapride or pimozide, which are metabolised by the hepatic isozyme CYP3A4, have been associated with QT interval prolongation and/or cardiac arrhythmias (typically torsades de pointes) as a result of an increase in their serum level subsequent to interaction with significant inhibitors of this isozyme, including some macrolide antibacterials. Although Roxithromycin-RL has no or limited ability to complex CYP3A4 and hence to inhibit the metabolism of other drugs processed by this isozyme, a potential for clinical interaction of Roxithromycin-RL with the above mentioned drugs cannot be either ascertained or ruled out in confidence. Thus, concomitant administration of Roxithromycin-RL and such drugs is not recommended. Warfarin. While no interaction was observed in volunteer studies, Roxithromycin-RL appears to interact with warfarin. Increases in prothrombin time (international normalised ratio (INR)) have been reported in patients treated concomitantly with Roxithromycin-RL and warfarin or the related vitamin K antagonist phenprocoumon, and severe bleeding episodes have occurred as a consequence. Digoxin and other cardiac glycosides. A study in healthy volunteers has shown that Roxithromycin-RL may increase the absorption of digoxin. This effect, common to other macrolides, may very rarely result in cardiac glycoside toxicity. This may be manifested by symptoms such as nausea, vomiting, diarrhoea, headache or dizziness. Cardiac glycoside toxicity may also elicit heart conduction and/or rhythm disorders. Consequently, in patients treated with Roxithromycin-RL and digoxin or another cardiac glycoside, ECG and, if possible, the serum level of the cardiac glycoside should be monitored. This is mandatory if symptoms suggesting cardiac glycoside overdosage have occurred. Midazolam. Roxithromycin-RL, like other macrolides, may increase the area under the midazolam concentration-time curve and the midazolam half-life. Thus, the effects of midazolam may be enhanced and prolonged in patients treated with Roxithromycin-RL. There is no conclusive evidence for an interaction between Roxithromycin-RL and triazolam. Cyclosporin. A slight increase in plasma concentrations of cyclosporin A has been observed. This does not generally necessitate altering the usual dosage.
Roxithromycin-RL side effects
Applies to benzoyl peroxide topical: topical bar, topical cream, topical foam, topical gel/jelly, topical liquid, topical lotion, topical pad, topical soap, topical solution
In addition to its needed effects, some unwanted effects may be caused by benzoyl peroxide topical (the active ingredient contained in Roxithromycin-RL). In the event that any of these side effects do occur, they may require medical attention.
Major Side Effects
You should check with your doctor immediately if any of these side effects occur when taking benzoyl peroxide topical:
Less common or rare:
- Painful irritation of skin, including burning, blistering, crusting, itching, severe redness, or swelling
- skin rash
- Difficult breathing
- swelling of the eyes, face, lips, or tongue
- tightness in the throat
If any of the following symptoms of overdose occur while taking benzoyl peroxide topical, get emergency help immediately:
Symptoms of overdose:
- Burning, itching, scaling, redness, or swelling of skin (severe)
Minor Side Effects
Some of the side effects that can occur with benzoyl peroxide topical may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:
- Dryness or peeling of the skin (may occur after a few days)
- feeling of warmth, mild stinging, and redness of the skin
Known allergy to macrolides.
Concomitant administration of Roxithromycin-RL with vasoconstrictive ergot (alkaloid) derivatives is contra-indicated since symptoms of ergotism have been described with other macrolides.
Active ingredient matches for Roxithromycin-RL:
Roxithromycin in Australia.
|Unit description / dosage (Manufacturer)||Price, USD|
|Tablet, Film-Coated; Oral; Roxithromycin 150 mg|
|Tablet, Film-Coated; Oral; Roxithromycin 300 mg|
List of Roxithromycin-RL substitutes (brand and generic names):
|Roxithromycin-ratiopharm (Czech Republic, Germany, Hungary)|
|Roxithromycine Actavis (France)|
|Roxithromycine Arrow (France)|
|Roxithromycine Biogaran (France)|
|Roxithromycine G Gam (France)|
|Roxithromycine Merck (France)|
|Roxithromycine Mylan (France)|
|Roxithromycine Qualimed (France)|
|Roxithromycine Ranbaxy (France)|
|Roxithromycine Ratiopharm (France)|
|Roxithromycine RPG (France)|
|Roxithromycine Sandoz (France)|
|Roxithromycine Teva (France)|
|Roxithromycine Winthrop (France, Tunisia)|
|Roxithromycine Zentiva (France)|
|Roxithromycine Zydus (France)|
|Roxithromycine-EG (Belgium, France, Luxembourg)|
|Roxithroxyl 150 mg x 10 Blister x 10 Tablet (Bangkok Lab & Cosmetic)|
|Roxithroxyl 150 mg x 100's (Bangkok Lab & Cosmetic)|
|Roxithroxyl 150 mg x 10 x 10's (Bangkok Lab & Cosmetic)|
|Roxithroxyl 300 mg x 10 x 10's (Bangkok Lab & Cosmetic)|
|Roxithroxyl film-coated tab 150 mg 10 x 10's (Bangkok Lab & Cosmetic)|
|Roxithroxyl film-coated tab 150 mg 100's (Bangkok Lab & Cosmetic)|
|Roxithroxyl film-coated tab 300 mg 10 x 10's (Bangkok Lab & Cosmetic)|
|ROXITID 150MG TABLET 1 strip / 10 tablets each (Ranbaxy Laboratories Ltd)||$ 0.68|
|Roxitil (South Korea)|
|Roxitin 150 mg x 50 x 10's (T P Drug)|
|Roxitin 150 mg x 500's (T P Drug)|
|ROXITIS Capsule/ Tablet / 150mg / 10 units (Medley)||$ 0.87|
|ROXITIS Dispersible Tablet / 50mg / 10 units (Medley)||$ 0.39|
|Roxitis 50mg TAB / 10 (Medley)||$ 0.39|
|Roxitis 150mg TAB / 10 (Medley)||$ 0.87|
|Roxitis 50mg/5mL SUSP / 30ml (Medley)||$ 0.47|
|50 mg x 10's (Medley)||$ 0.39|
|150 mg x 10's (Medley)||$ 0.87|
|50 mg x 5 mL x 30ml (Medley)||$ 0.47|
|Roxitis 150 mg x 10 Blister x 10 Tablet (Medley)|
|ROXITIS tab 50 mg x 10's (Medley)||$ 0.39|
|ROXITIS tab 150 mg x 10's (Medley)||$ 0.87|
|ROXITIS oral susp 50 mg x 5 mL x 30ml (Medley)||$ 0.47|
|Roxitis 50mg TAB / 10 (Medley)||$ 0.39|
- PubChem. "roxithromycin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "roxithromycin". http://www.drugbank.ca/drugs/DB00778 (accessed September 17, 2018).
- DTP/NCI. "roxithromycin: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Roxithromycin-RL are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Roxithromycin-RL. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported usefulNo survey data has been collected yet
Consumer reported price estimatesNo survey data has been collected yet
Consumer reported time for resultsNo survey data has been collected yet
Consumer reported ageNo survey data has been collected yet
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology